What is the share price of Dr. Lal PathLabs Ltd (LALPATHLAB) today?
The share price of LALPATHLAB as on 5th December 2025 is ₹2993.80. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Dr. Lal PathLabs Ltd (LALPATHLAB) share?
The past returns of Dr. Lal PathLabs Ltd (LALPATHLAB) share are- Past 1 week: -3.85%
- Past 1 month: -7.62%
- Past 3 months: -7.99%
- Past 6 months: 7.15%
- Past 1 year: 2.80%
- Past 3 years: 23.24%
- Past 5 years: 36.52%
What are the peers or stocks similar to Dr. Lal PathLabs Ltd (LALPATHLAB)?
The peers or stocks similar to Dr. Lal PathLabs Ltd (LALPATHLAB) include:What is the dividend yield % of Dr. Lal PathLabs Ltd (LALPATHLAB) share?
The current dividend yield of Dr. Lal PathLabs Ltd (LALPATHLAB) is 0.79.What is the market cap of Dr. Lal PathLabs Ltd (LALPATHLAB) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Dr. Lal PathLabs Ltd (LALPATHLAB) is ₹25491.69 Cr as of 5th December 2025.What is the 52 week high and low of Dr. Lal PathLabs Ltd (LALPATHLAB) share?
The 52-week high of Dr. Lal PathLabs Ltd (LALPATHLAB) is ₹3540 and the 52-week low is ₹2293.55.What is the PE and PB ratio of Dr. Lal PathLabs Ltd (LALPATHLAB) stock?
The P/E (price-to-earnings) ratio of Dr. Lal PathLabs Ltd (LALPATHLAB) is 52.33. The P/B (price-to-book) ratio is 11.55.Which sector does Dr. Lal PathLabs Ltd (LALPATHLAB) belong to?
Dr. Lal PathLabs Ltd (LALPATHLAB) belongs to the Health Care sector & Hospitals & Diagnostic Centres sub-sector.How to buy Dr. Lal PathLabs Ltd (LALPATHLAB) shares?
You can directly buy Dr. Lal PathLabs Ltd (LALPATHLAB) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Dr. Lal PathLabs Ltd
LALPATHLAB Share Price
2,993.801.97% (-60.30)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
LALPATHLAB Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
LALPATHLAB Performance & Key Metrics
LALPATHLAB Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 47.71 | 11.55 | 0.79% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.94 | 5.83 | 0.58% |
71%
Analysts have suggested that investors can buy this stock
from 24 analysts
Price Upside
Earnings Growth
Rev. Growth
LALPATHLAB Company Profile
Dr Lal Pathlabs Private Limited is headquartered in Gurgaon, Haryana, India and is a medical laboratory operator.
MAXHEALTH
PE Ratio
98.00
98.00
1Y Return
1.85%
1.85%
Buy Reco %
77.27
77.27
APOLLOHOSP
PE Ratio
71.61
71.61
1Y Return
0.43%
0.43%
Buy Reco %
86.21
86.21
FORTIS
PE Ratio
86.64
86.64
1Y Return
24.99%
24.99%
Buy Reco %
75.00
75.00
PE Ratio
49.80
49.80
1Y Return
47.18%
47.18%
Buy Reco %
77.78
77.78
ASTERDM
PE Ratio
6.28
6.28
1Y Return
34.87%
34.87%
Buy Reco %
100.00
100.00
LALPATHLAB Sentiment Analysis
LALPATHLAB Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
LALPATHLAB Stock Summary · August 2025
In Q1 FY26, the company demonstrated robust financial performance with an 11.3% revenue increase and a 24.3% rise in profit after tax, largely driven by the successful SwasthFit portfolio and advancements in high-complexity testing. While the Indian healthcare diagnostics sector presents significant growth opportunities, particularly in underserved markets, challenges such as infrastructure development and the transition to a franchise model have impacted top-line growth. The integration of technology, including AI, is enhancing operational efficiency, yet management cautions that current gross margins may not be sustainable due to anticipated investments. As the company expands its genomic and specialized testing offerings, it remains focused on maintaining quality service delivery amidst a competitive landscape. Overall, the outlook is positive, supported by a strategic emphasis on digital transformation and market expansion.
LALPATHLAB Stock Growth Drivers
LALPATHLAB Stock Growth Drivers
7Strong Financial Performance
The company reported an 11.3% increase in revenues and a 24.3% rise in profit after
Expansion of Operations
The company has been steadily expanding its operations, particularly in underserved markets such as Tier-2
LALPATHLAB Stock Challenges
LALPATHLAB Stock Challenges
4Margin Compression Concerns
The company is facing potential margin compression, as indicated by the acknowledgment that the current
Challenges in Collection Network
The company has encountered significant challenges with its collection network, particularly due to a decline
LALPATHLAB Forecast
LALPATHLAB Forecasts
Price
Revenue
Earnings
LALPATHLAB Share Price Forecast
LALPATHLAB Share Price Forecast
2025
Current
₹3,054.10
Baseline
Forecast for Dec 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹3,054.10
Baseline
Forecast for Dec 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
LALPATHLAB Company Revenue Forecast
LALPATHLAB Company Revenue Forecast
2025
Current
₹2.55
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹2.55
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
LALPATHLAB Stock EPS (Earnings Per Share) Forecast
LALPATHLAB Stock EPS (Earnings Per Share) Forecast
2025
Current
₹58.32
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹58.32
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
LALPATHLAB
LALPATHLAB
Income
Balance Sheet
Cash Flow
Annual Normal View
LALPATHLAB Income Statement
LALPATHLAB Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 939.92 | 1,088.14 | 1,249.37 | 1,385.41 | 1,632.60 | 2,139.96 | 2,058.60 | 2,295.81 | 2,554.83 | 2,703.50 | ||||||||||
Raw Materials | 197.08 | 226.03 | 262.35 | 298.70 | 397.26 | 502.25 | 447.15 | 451.42 | 481.46 | 1,860.30 | ||||||||||
| Power & Fuel Cost | 13.58 | 15.32 | 15.74 | 16.74 | 18.63 | 22.11 | 25.91 | 26.18 | 27.16 | |||||||||||
| Employee Cost | 152.01 | 180.75 | 208.29 | 242.64 | 273.70 | 364.94 | 376.52 | 424.57 | 482.36 | |||||||||||
| Selling & Administrative Expenses | 149.29 | 175.89 | 208.79 | 184.69 | 176.29 | 253.82 | 270.25 | 275.58 | 308.24 | |||||||||||
| Operating & Other expenses | 162.90 | 194.94 | 214.59 | 244.00 | 279.11 | 383.56 | 407.22 | 439.65 | 466.58 | |||||||||||
EBITDA | 265.06 | 295.21 | 339.61 | 398.64 | 487.61 | 613.28 | 531.55 | 678.41 | 789.03 | 843.20 | ||||||||||
| Depreciation/Amortization | 27.54 | 33.06 | 38.22 | 72.81 | 77.20 | 108.11 | 150.19 | 143.60 | 141.92 | 147.00 | ||||||||||
| PBIT | 237.52 | 262.15 | 301.39 | 325.83 | 410.41 | 505.17 | 381.36 | 534.81 | 647.11 | 696.20 | ||||||||||
| Interest & Other Items | 0.70 | 0.84 | 0.84 | 15.31 | 16.00 | 30.18 | 37.53 | 29.36 | 22.31 | 19.80 | ||||||||||
| PBT | 236.82 | 261.31 | 300.55 | 310.52 | 394.41 | 474.99 | 343.83 | 505.45 | 624.80 | 676.40 | ||||||||||
| Taxes & Other Items | 82.23 | 90.59 | 101.37 | 84.56 | 102.79 | 130.15 | 104.98 | 147.72 | 137.66 | 142.10 | ||||||||||
| Net Income | 154.59 | 170.72 | 199.18 | 225.96 | 291.62 | 344.84 | 238.85 | 357.73 | 487.14 | 534.30 | ||||||||||
| EPS | 18.65 | 20.52 | 23.90 | 27.11 | 34.99 | 41.38 | 28.65 | 42.88 | 58.32 | 63.92 | ||||||||||
| DPS | 3.00 | 4.50 | 6.00 | 12.00 | 20.00 | 12.00 | 12.00 | 24.00 | 24.00 | 24.00 | ||||||||||
| Payout ratio | 0.16 | 0.22 | 0.25 | 0.44 | 0.57 | 0.29 | 0.42 | 0.56 | 0.41 | 0.38 |
LALPATHLAB Company Updates
FY 2026FY 2026
Investor Presentation
Oct 31PDF
Jul 31PDF
LALPATHLAB Stock Peers
LALPATHLAB Past Performance & Peer Comparison
LALPATHLAB Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareHospitals & Diagnostic Centres
Compare valuation on Screener
Health CareHospitals & Diagnostic Centres
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Dr. Lal PathLabs Ltd | 52.33 | 11.55 | 0.79% |
| Max Healthcare Institute Ltd | 98.00 | 11.24 | 0.14% |
| Apollo Hospitals Enterprise Ltd | 71.61 | 9.33 | 0.18% |
| Fortis Healthcare Ltd | 86.64 | 7.32 | 0.11% |
LALPATHLAB Stock Price Comparison
Compare LALPATHLAB with any stock or ETFCompare LALPATHLAB with any stock or ETF
LALPATHLAB
LALPATHLAB Holdings
LALPATHLAB Shareholdings
LALPATHLAB Promoter Holdings Trend
LALPATHLAB Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
LALPATHLAB Institutional Holdings Trend
LALPATHLAB Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
LALPATHLAB Shareholding Pattern
LALPATHLAB Shareholding Pattern
LALPATHLAB Shareholding History
LALPATHLAB Shareholding History
Foreign Institutions
Mutual Funds Invested in LALPATHLAB
Mutual Funds Invested in LALPATHLAB
No mutual funds holding trends are available
Top 5 Mutual Funds holding Dr. Lal PathLabs Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 2.4600% | Percentage of the fund’s portfolio invested in the stock 0.69% | Change in the portfolio weight of the stock over the last 3 months -0.13% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 32/59 (-5) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.4374% | Percentage of the fund’s portfolio invested in the stock 1.43% | Change in the portfolio weight of the stock over the last 3 months -0.18% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 23/62 (-3) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.0123% | Percentage of the fund’s portfolio invested in the stock 1.06% | Change in the portfolio weight of the stock over the last 3 months 0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 55/80 (-2) |
Compare 3-month MF holding change on Screener
smallcases containing LALPATHLAB stock
smallcases containing LALPATHLAB stock
Looks like this stock is not in any smallcase yet.
LALPATHLAB Events
LALPATHLAB Events
LALPATHLAB Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.79%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹7.87 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
LALPATHLAB Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.79%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹7.87 every year
LALPATHLAB Upcoming Dividends
LALPATHLAB Upcoming Dividends
No upcoming dividends are available
LALPATHLAB Past Dividends
LALPATHLAB Past Dividends
Cash Dividend
Ex DateEx DateNov 7, 2025
Interim 2
Interim 2 | Div/Share: ₹7.00
Dividend/Share
₹7.00
Ex DateEx Date
Nov 7, 2025
Cash Dividend
Ex DateEx DateAug 6, 2025
Interim
Interim | Div/Share: ₹6.00
Dividend/Share
₹6.00
Ex DateEx Date
Aug 6, 2025
Cash Dividend
Ex DateEx DateJun 6, 2025
Final
Final | Div/Share: ₹6.00
Dividend/Share
₹6.00
Ex DateEx Date
Jun 6, 2025
Cash Dividend
Ex DateEx DateFeb 5, 2025
Interim 3
Interim 3 | Div/Share: ₹6.00
Dividend/Share
₹6.00
Ex DateEx Date
Feb 5, 2025
Cash Dividend
Ex DateEx DateNov 5, 2024
Interim 2
Interim 2 | Div/Share: ₹6.00
Dividend/Share
₹6.00
Ex DateEx Date
Nov 5, 2024
LALPATHLAB Stock News & Opinions
LALPATHLAB Stock News & Opinions
Articles & Videos
Corporate
Dr Lal Pathlabs approves bonus issue of 1:1
The board of Dr Lal Pathlabs at its meeting held on 31 October 2025 has approved bonus issue of 1:1. Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Board of Dr. Lal PathLabs recommends interim dividend
Dr. Lal PathLabs announced that the Board of Directors of the Company at its meeting held on 31 October 2025, inter alia, have recommended the interim dividend of Rs 7 per equity Share (i.e. 70%) , subject to the approval of the shareholders.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Dr Lal Pathlabs fixes record date for 2nd interim dividend
Dr Lal Pathlabs has fixed 07 November 2025 as record date for purpose of 2nd interim dividend of Rs 7 per equity share for FY 2025-26. Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Dr Lal Pathlabs consolidated net profit rises 16.41% in the September 2025 quarter
Net profit of Dr Lal Pathlabs rose 16.41% to Rs 150.40 crore in the quarter ended September 2025 as against Rs 129.20 crore during the previous quarter ended September 2024. Sales rose 10.66% to Rs 730.60 crore in the quarter ended September 2025 as against Rs 660.20 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales730.60660.20 11 OPM %30.6730.67 - PBDT244.10218.40 12 PBT203.60183.10 11 NP150.40129.20 16 Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Dr Lal Pathlabs gains as board to mull bonus issue plan on 31st Oct'25
Additionally, the board will consider and approve unaudited standalone & consolidated financial results for the quarter and half year ended 30 September 2025. Further, the company's board will also consider the declaration of 2nd interim dividend, if any, on the company's equity shares for FY26. Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. The company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The company's consolidated net profit jumped 24.4% to Rs 132.40 crore on 11.3% increase in net sales to Rs 669.80 crore in Q1 FY26 over Q1 FY25.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Dr. Lal PathLabs to hold board meeting
Dr. Lal PathLabs will hold a meeting of the Board of Directors of the Company on 31 October 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Dr Lal Pathlabs approves proposal for acquisition of immovable property
The board of Dr Lal Pathlabs at its meeting held on 23 September 2025 has approved the proposal for acquisition of immovable property situated in New Delhi for a consideration of up to Rs 74.51 crore. Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Dr. Lal PathLabs adopts AI-powered diagnostics for cancer detection
Dr. Lal PathLabs (DLPL) has become the first laboratory in the country to adopt a deep learning-based AI module to detect lymph node metastasis, including micrometastasis, in cancer cases. This cutting edge technology, validated in collaboration with Qritive, was showcased at USCAP 2025 one of the world's leading pathology conferences. Accurate identification of cancer spread to lymph nodes is vital in determining the stage and treatment path for patients. If the spread of cancer to the lymph nodes is left undetected, it can allow the disease to progress to later stages, increasing the risk of metastasis to distant organs and significantly reducing survival rates. Therefore, the identification of occult metastases in patients with early-stage cancer could have a substantial clinical impact on treatment planning and optimal therapy for patients with cancer. Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Board of Dr. Lal PathLabs recommends interim dividend
Dr. Lal PathLabs announced that the Board of Directors of the Company at its meeting held on 31 July 2025, inter alia, have recommended the interim dividend of Rs 6 per equity Share (i.e. 60%) , subject to the approval of the shareholders.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Dr Lal Pathlabs fixes record date for interim dividend
Dr Lal Pathlabs has fixed 06 August 2025 as record date for interim dividend of Rs 6 per share for FY 2025-26. Powered by Capital Market - Live
4 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 13.02%, vs industry avg of 13.4%
Over the last 5 years, market share decreased from 3.32% to 3.2%
Over the last 5 years, net income has grown at a yearly rate of 16.61%, vs industry avg of 42.46%